Evidence map›Paper›PMID 41936038›Full record

ArticleMultiple sclerosis (Houndmills, Basingstoke, England)2026

Impact of cancer on multiple sclerosis-related healthcare and disease-modifying drug use: A multinational cohort study.

Chloe Pierret, Geraldine Androdias, Christine Lebrun-Frenay, Sandra Vukusic, Myriam Maumy, Huah Shin Ng, Feng Zhu, Helen Tremlett, Emmanuelle Leray

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chloe PierretEcole des Hautes Etudes en Sante Publique, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes University, Rennes, France.ORCID 0009-0006-2702-3343
Geraldine AndrodiasService de Neurologie, Sclérose en plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France.ORCID 0009-0002-1016-0828
Christine Lebrun-FrenayNice Cote d'Azur UR2CA-URRIS, CRCSEP Centre Hospitalier Universitaire de Nice, Nice, France.ORCID 0000-0002-3713-2416
Sandra VukusicService de Neurologie, Sclérose en plaques, Pathologies de la Myéline et Neuro-Inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Bron, France; Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France; Observatoire Français de la Sclérose en Plaques, Centre de Recherche en Neurosciences de Lyon, INSERM 1028 et CNRS UMR 5292, Lyon, France; Eugène Devic EDMUS Foundation against Multiple Sclerosis, Lyon, France.ORCID 0000-0001-7337-7122
Myriam MaumyEcole des Hautes Etudes en Sante Publique, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes University, Rennes, France.
Huah Shin NgCollege of Medicine and Public Health, Flinders University, Adelaide, SA, Australia; SA Pharmacy, SA Health, Northern Adelaide Local Health Network, Adelaide, SA, Australia.ORCID 0000-0001-8381-5253
Feng ZhuFaculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.
Helen TremlettFaculty of Medicine (Neurology) and the Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada.ORCID 0000-0001-5804-2535
Emmanuelle LerayEcole des Hautes Etudes en Sante Publique, CNRS, Inserm, ARENES UMR 6051, RSMS U 1309, Rennes University, Rennes, France.ORCID 0000-0001-8424-4499

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNeurological care and disease-modifying therapies (DMTs) are central to multiple sclerosis (MS) management, but how comorbidities like cancer affect them remains unclear.

objectiveWe assessed the impact of cancer on MS-related healthcare and DMT use.

methodsThis cohort study accessed population-based data from France (2009-2021) and British Columbia, Canada (1991-2020). Cases were individuals with MS diagnosed with an incident cancer. The 4-year study period encompassed the 2 years before and after the cancer diagnosis. Each case was matched to two cancer-free individuals with MS (i.e. controls). Outcomes were neurologist visit rates, MS hospitalization rates, and percentage of DMT users. Mixed-effects models were used with a knot at cancer diagnosis. Incidence rate ratios (IRRs) were estimated pre- and post-cancer (cases vs. controls) and compared using a slope ratio (SR).

resultsIn total, 6902 cases were matched to 13,804 controls. There was a negative effect of cancer on DMT use (SR = 0.36 [0.19-0.70]), especially among those on chemotherapy (SR = 0.24 [0.14-0.40]). Neurologist visit IRRs did not differ pre- and post-cancer (SR = 0.96 [0.91-1.005]). Similarly, MS hospitalization IRRs did not differ (SR = 1.06 [0.84-1.33]).

conclusionFollowing cancer, DMT use declined sharply. However, there was no evidence of a strong impact of cancer on neurologist visits and MS hospitalizations.

Indexed as

HospitalizationImmunologic FactorsMultiple SclerosisNeoplasmsAdultBritish ColumbiaCohort StudiesComorbidityFemaleFranceHumansMaleMiddle AgedImmunologic Factorscancerdisease-modifying therapiesepidemiologyhealthcare useMultiple sclerosis

Identifiers

PMID41936038
PMCPMC13100324

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.